Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 64 articles:
HTML format

Single Articles

    January 2023
  1. BOGERS S, Zimmermann H, Ndong A, Davidovich U, et al
    Mapping hematologists' HIV testing behavior among lymphoma patients-A mixed-methods study.
    PLoS One. 2023;18:e0279958.
    PubMed     Abstract available

  2. VAUGHAN J, Wiggill T, Lawrie D, Machaba M, et al
    The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma.
    PLoS One. 2023;18:e0280044.
    PubMed     Abstract available

  3. Expression of Concern: Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication.
    PLoS One. 2023;18:e0278797.

  4. PETERSEN MI, Carignano HA, Mongini C, Gonzalez DD, et al
    Bovine leukemia virus encoded blv-miR-b4-3p microRNA is associated with reduced expression of anti-oncogenic gene in vivo.
    PLoS One. 2023;18:e0281317.
    PubMed     Abstract available

  5. THEAKSTONE AG, Brennan PM, Jenkinson MD, Goodacre R, et al
    Investigating centrifugal filtration of serum-based FTIR spectroscopy for the stratification of brain tumours.
    PLoS One. 2023;18:e0279669.
    PubMed     Abstract available

  6. SONOWAL H, Rice WG, Howell SB
    Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma.
    PLoS One. 2023;18:e0277003.
    PubMed     Abstract available

  7. SARA M, Minelli C, Broccia G, Vineis P, et al
    COVID-19 and non-Hodgkin's lymphoma: A common susceptibility pattern?
    PLoS One. 2023;18:e0277588.
    PubMed     Abstract available

  8. KOZAKI R, Yasuhiro T, Kato H, Murai J, et al
    Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
    PLoS One. 2023;18:e0282166.
    PubMed     Abstract available

  9. USTASZEWSKI A, Paczkowska J, Janiszewska J, Bernhart SH, et al
    Identification of two unannotated miRNAs in classic Hodgkin lymphoma cell lines.
    PLoS One. 2023;18:e0283186.
    PubMed     Abstract available

  10. GEORGI TW, Kurch L, Hasenclever D, Warbey VS, et al
    Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions.
    PLoS One. 2023;18:e0283694.
    PubMed     Abstract available

  11. SCHNEIDER DA, Lehmkuhl AD, Spraker TR, Dittmar RO, et al
    Tonsil biopsy to detect chronic wasting disease in white-tailed deer (Odocoileus virginianus) by immunohistochemistry.
    PLoS One. 2023;18:e0282356.
    PubMed     Abstract available

  12. SUN R, Guo S, Shuda Y, Chakka AB, et al
    Mitotic CDK1 and 4E-BP1 I: Loss of 4E-BP1 serine 82 phosphorylation promotes proliferative polycystic disease and lymphoma in aged or sublethally irradiated mice.
    PLoS One. 2023;18:e0282722.
    PubMed     Abstract available

  13. Retraction: Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis.
    PLoS One. 2023;18:e0286175.

  14. LIN L, Wang D, Chen H
    The characteristics and survival of second primary lung cancer after Hodgkin's lymphoma: A comparison with first primary lung cancer using the SEER database.
    PLoS One. 2023;18:e0285766.
    PubMed     Abstract available

    January 2022
  15. DE MEL S, Mustafa N, Selvarajan V, Azaman MI, et al
    T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival.
    PLoS One. 2022;17:e0261469.
    PubMed     Abstract available

  16. HARVEY MJ, Zhong Y, Morris E, Beverage JN, et al
    Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
    PLoS One. 2022;17:e0261336.
    PubMed     Abstract available

  17. BROCCIA G, Carter J, Ozsin-Ozler C, Meloni F, et al
    Incidence of non-Hodgkin's lymphoma among adults in Sardinia, Italy.
    PLoS One. 2022;17:e0260078.
    PubMed     Abstract available

  18. WORONIECKA R, Rymkiewicz G, Szafron LM, Blachnio K, et al
    Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature.
    PLoS One. 2022;17:e0263980.
    PubMed     Abstract available

  19. HOWELL DA, McCaughan D, Smith AG, Patmore R, et al
    Incurable but treatable: Understanding, uncertainty and impact in chronic blood cancers-A qualitative study from the UK's Haematological Malignancy Research Network.
    PLoS One. 2022;17:e0263672.
    PubMed     Abstract available

  20. SU YC, Chiu BC, Li HJ, Yang WC, et al
    Investigation of the incidence trend of follicular lymphoma from 2008 to 2017 in Taiwan and the United States using population-based data.
    PLoS One. 2022;17:e0265543.
    PubMed     Abstract available

  21. GEORGI TW, Zieschank A, Kornrumpf K, Kurch L, et al
    Automatic classification of lymphoma lesions in FDG-PET-Differentiation between tumor and non-tumor uptake.
    PLoS One. 2022;17:e0267275.
    PubMed     Abstract available

  22. MALENGE MM, Maaland AF, Repetto-Llamazares A, Middleton B, et al
    Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.
    PLoS One. 2022;17:e0267543.
    PubMed     Abstract available

  23. GROS A, Menguy S, Bobee V, Ducharme O, et al
    Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling.
    PLoS One. 2022;17:e0266978.
    PubMed     Abstract available

  24. LOPEZ-JIMENEZ T, Duarte-Salles T, Plana-Ripoll O, Recalde M, et al
    Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.
    PLoS One. 2022;17:e0264634.
    PubMed     Abstract available

  25. KAWAHIRA M, Kanmura S, Mizuno K, Machida K, et al
    Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
    PLoS One. 2022;17:e0267572.
    PubMed     Abstract available

  26. TSUTSUE S, Makita S, Yi J, Crawford B, et al
    Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis.
    PLoS One. 2022;17:e0269169.
    PubMed     Abstract available

  27. OGISO A, Mizuno T, Ito K, Mizokami F, et al
    Use of benzodiazepines is the risk factor for infection in patients aged 80 years or older with diffuse large B-cell lymphoma: A single-institution retrospective study.
    PLoS One. 2022;17:e0269362.
    PubMed     Abstract available

  28. HAYAKAWA J, Seki T, Kawazoe Y, Ohe K, et al
    Pathway importance by graph convolutional network and Shapley additive explanations in gene expression phenotype of diffuse large B-cell lymphoma.
    PLoS One. 2022;17:e0269570.
    PubMed     Abstract available

  29. CULLEN JN, Martin J, Vilella AJ, Treeful A, et al
    Development and application of a next-generation sequencing protocol and bioinformatics pipeline for the comprehensive analysis of the canine immunoglobulin repertoire.
    PLoS One. 2022;17:e0270710.
    PubMed     Abstract available

  30. RIGTER LS, Snaebjornsson P, Rosenberg EH, Altena E, et al
    Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer.
    PLoS One. 2022;17:e0270591.
    PubMed     Abstract available

  31. JONA A, Kenyeres A, Barna S, Illes A, et al
    Clinical and biological prognostic factors in follicular lymphoma patients.
    PLoS One. 2022;17:e0272787.
    PubMed     Abstract available

  32. AL-KHATIB S, Shabaneh A, Abdo N, Al-Eitan L, et al
    Association of TLR9-1237T>C; rs5743836 polymorphism with increased risk of Hodgkin's lymphoma: A case-control study.
    PLoS One. 2022;17:e0272312.
    PubMed     Abstract available

  33. YOON S, Yoo KH, Park SH, Kim H, et al
    Low-dose abdominopelvic computed tomography in patients with lymphoma: An image quality and radiation dose reduction study.
    PLoS One. 2022;17:e0272356.
    PubMed     Abstract available

  34. DONG K, Heidari M, Mays J, Chang S, et al
    A comprehensive analysis of avian lymphoid leukosis-like lymphoma transcriptomes including identification of LncRNAs and the expression profiles.
    PLoS One. 2022;17:e0272557.
    PubMed     Abstract available

  35. GONDWE Y, Kudowa E, Tomoka T, Kasonkanji ED, et al
    Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy.
    PLoS One. 2022;17:e0273408.
    PubMed     Abstract available

  36. RAPITI N, Abdelatif N, Moosa MS
    Prognostic variables and 4-year survival outcomes in CD20 Positive AIDS-Related Lymphoma in the Anti-retroviral treatment era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa.
    PLoS One. 2022;17:e0272282.
    PubMed     Abstract available

  37. KULKA M, Brennan K, Mc Gee M
    Investigation of canine extracellular vesicles in diffuse large B-cell lymphomas.
    PLoS One. 2022;17:e0274261.
    PubMed     Abstract available

  38. CHOI JH, Lim I, Byun BH, Kim BI, et al
    The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
    PLoS One. 2022;17:e0273839.
    PubMed     Abstract available

  39. KIBRET YM, Leka YA, Tekle NF, Tigeneh W, et al
    Patterns of cancer in Wolaita Sodo University Hospital: South Ethiopia.
    PLoS One. 2022;17:e0274792.
    PubMed     Abstract available

  40. JAIRATH NK, Bardhi R, Runge JS, Bledea R, et al
    Predictors of large cell transformation in patients with Sezary Syndrome-A retrospective analysis.
    PLoS One. 2022;17:e0277655.
    PubMed     Abstract available

  41. Expression of Concern: Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis.
    PLoS One. 2022;17:e0277763.

  42. DELLA PIA A, Kim GYG, Ip A, Ahn J, et al
    Anti-spike antibody response to the COVID vaccine in lymphoma patients.
    PLoS One. 2022;17:e0266584.
    PubMed     Abstract available

  43. LIN M, Wu S
    Ultrasound classification of non-mass breast lesions following BI-RADS presents high positive predictive value.
    PLoS One. 2022;17:e0278299.
    PubMed     Abstract available

  44. GURNEY J, Stanley J, Teng A, Krebs J, et al
    Cancer and diabetes co-occurrence: A national study with 44 million person-years of follow-up.
    PLoS One. 2022;17:e0276913.
    PubMed     Abstract available

  45. Expression of Concern: A transcriptional signature associated with non-Hodgkin lymphoma in the blood of patients with Q fever.
    PLoS One. 2022;17:e0279044.

  46. CHACIM S, Monjardino T, Cunha JL, Medeiros P, et al
    Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center.
    PLoS One. 2022;17:e0278950.
    PubMed     Abstract available

    January 2021
  47. MORIBE F, Nishikori M, Takashima T, Taniyama D, et al
    Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.
    PLoS One. 2021;16:e0237554.
    PubMed     Abstract available

  48. HSU CH, Tomiyasu H, Liao CH, Lin CS, et al
    Genome-wide DNA methylation and RNA-seq analyses identify genes and pathways associated with doxorubicin resistance in a canine diffuse large B-cell lymphoma cell line.
    PLoS One. 2021;16:e0250013.
    PubMed     Abstract available

  49. SLOAN SL, Renaldo KA, Long M, Chung JH, et al
    Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
    PLoS One. 2021;16:e0250839.
    PubMed     Abstract available

  50. KE Q, Liao CC, Tan XH, Guo BP, et al
    Diagnostic accuracy of pelvic magnetic resonance imaging for the assessment of bone marrow involvement in diffuse large B-cell lymphoma.
    PLoS One. 2021;16:e0252226.
    PubMed     Abstract available

  51. TAKASHIMA Y, Kawaguchi A, Fukai J, Iwadate Y, et al
    Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma.
    PLoS One. 2021;16:e0251272.
    PubMed     Abstract available

  52. FAUZI YR, Nakahata S, Chilmi S, Ichikawa T, et al
    Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-kappaB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.
    PLoS One. 2021;16:e0256320.
    PubMed     Abstract available

  53. VON BEEK C, Alriksson L, Palle J, Gustafson AM, et al
    Dynamin inhibition causes context-dependent cell death of leukemia and lymphoma cells.
    PLoS One. 2021;16:e0256708.
    PubMed     Abstract available

  54. AMBROSE C, Su L, Wu L, Dufort FJ, et al
    Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    PLoS One. 2021;16:e0247701.
    PubMed     Abstract available

  55. PETRENKO O, Li J, Cimica V, Mena-Taboada P, et al
    IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.
    PLoS One. 2021;16:e0247394.
    PubMed     Abstract available

  56. MASLE-FARQUHAR E, Russell A, Li Y, Zhu F, et al
    Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice.
    PLoS One. 2021;16:e0237830.
    PubMed     Abstract available

  57. OTA Y, Yoda H, Inoue T, Watanabe T, et al
    Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
    PLoS One. 2021;16:e0257718.
    PubMed     Abstract available

  58. MOSQUERA ORGUEIRA A, Ferreiro Ferro R, Diaz Arias JA, Aliste Santos C, et al
    Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
    PLoS One. 2021;16:e0248886.
    PubMed     Abstract available

  59. EVANGELISTA-LEITE D, Affonso Madaloso B, Shouta Yamashita B, Enrico Aloise F, et al
    Treating chronic diarrhea: A systematic review on Immunoproliferative Small Intestinal Disease (IPSID).
    PLoS One. 2021;16:e0253695.
    PubMed     Abstract available

  60. KIM RY, Park JH, Kim M, Park YG, et al
    Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
    PLoS One. 2021;16:e0260469.
    PubMed     Abstract available

  61. NAGEL S, Meyer C
    Establishment of the TBX-code reveals aberrantly activated T-box gene TBX3 in Hodgkin lymphoma.
    PLoS One. 2021;16:e0259674.
    PubMed     Abstract available

  62. PAIK H, Kim J
    Condensed trajectory of the temporal correlation of diseases and mortality extracted from over 300,000 patients in hospitals.
    PLoS One. 2021;16:e0257894.
    PubMed     Abstract available

  63. LIAO N, Koehne T, Tuckermann J, Triviai I, et al
    Osteoblast-specific inactivation of p53 results in locally increased bone formation.
    PLoS One. 2021;16:e0249894.
    PubMed     Abstract available

  64. BRAGA M, Leow CH, Gil JH, Teh JH, et al
    Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.
    PLoS One. 2021;16:e0260186.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.